Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (6269)	1/13/1999 12:38:00 PM
From: Mao II	Respond to of 43080

Here is the ENMD news: Dow Jones Online News, Friday, January 08, 1999 at 16:26 WASHINGTON -(Dow Jones)- Biotechnology firm EntreMed Inc. shares climbed Friday after the journal Cancer Research published an article that appears to confirm the effects of endostatin, its highly touted antitumor agent. EntreMed made headlines last spring when it was widely reported that endostatin, a protein, killed tumors in mice. Later in the year, however, some researchers said the promising results couldn't be duplicated. The latest results, published in an abstract in the Jan. 1 edition of Cancer Research, said further research provides "formal proof" that endostatin stops tumor cell reproduction. In Friday trading, shares of EntreMed (ENMD) advanced $4.625, or 22%, to settle at $25.50. EntredMed licensed the agents endostatin and angiostatin from Children's Hospital in Boston, where noted researcher Judah Folkman said he has found that endostatin can cause large tumors in mice to shrink and lie dormant, and that this plus a second agent called angiostatin can make such tumors vanish. The agents are believed to work by cutting off the blood supply to tumors. Until now, however, other scientists have said they haven't been able to duplicate his succcess. Besides EntreMed, other drug companies studying one or both of the agents include Bristol-Myers Squibb Co., Genentech Inc. and others. Vanguard Capital analyst Stephen G. Brozak said the data in Cancer Research "solidly reinforces the potential for endostatin." Brozak expects EntreMed to reap the benefits of its discoveries soon. "This article gives validation to endostatin in halting tumor cell reproduction," he said. In Cancer Research, published by the American Association for Cancer Research, the endostatin data comes from researchers from Beth Israel Deaconess Medical Center and Harvard Medical School. The report from the researchers, who looked at mice with cancerous kidney cells, said, "A 2.5-fold decrease in tumor volume was observed on the fifth day after treatment between control and treated groups. The growth of the tumor was suppressed in all of the treatment groups: a slower rate was seen compared with the control group. "Endostatin administration didn't inhibit tumor growth completely: the growth of the tumors slowed, with a marginal increase in volume during the treatment period." Van Kasper & Co. analyst Alan Auerbach said the published data is very important to EntreMed. "There have been definite concerns because of the inability of certain researchers to duplicate EntreMed's data," he said. "This report in Cancer Research is probably the first of many." Auerbach said EntreMed's stock is closely watched because cancer has touched most people's lives. "Cancer is one of the leading killers in the U.S.," he said. "If this drug makes an impact on this disease, it will mean a great deal to everyone alive. The company is getting so much attention because this could be a drug that touches everybody." Copyright (c) 1999 Dow Jones & Company, Inc. All Rights Reserved. Companies or Securities discussed in this article: Symbol Name NASDAQ:ENMD Entremed Inc Regards, M2